UniProt Accession Number of Target Protein: O14763

Alternative Name(s) of Target: death receptor 5; TRAIL receptor 2; TRAILR2; tumor necrosis factor receptor superfamily member 10B; TNFRSF10B; CD262; apomabImmunogen: The variable domains of this antibody were derived as scFv from a human antibody phage display library, with biotinylated DR5-Fc used to capture DR5-specific phage. The scFv obtained were subsequently reformatted into full-length antibodies.

Specificity: This antibody is specific for human death receptor 5, a proapoptotic receptor widely expressed in adult and fetal tissues, with notably high expression on tumour cells. Activation of DR5 triggers apoptosis in various types of cancer cells, without affecting most normal cell types.

Application Notes: This antibody binds DR5, triggering DR5 clustering and DISC activation in a range of cancer cells, including colorectal cancer and NSCLC cells (Adams, 2009). Conversely, this antibody showed no effector caspase activation or cell death induction in normal human hepatocytes. In vivo, this antibody has been shown toinhibit tumor xenograft growth in a variety of animal models (Varfolomeev, 2009). This antibody was used in IP, immunoblot, ELISA and IF analysis to precisely characterise its interaction with the DR5 ligand (Adams, 2009).

Antibody first published in:Adams et al.Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.Cell Death Differ. 2008 Apr;15(4):751-61PMID:18219321Note on publication:Describes the generation of this antibody from a phage display library, and subsequent characterisation of its binding specificity.